Acquisition of APIRx

For personal use only Ophthalmic conditions Problem Hundres of millions of people suffer from eye diseases and disorders where inflammation is a contributing factor. Available treatments have inadequate response for many patients and often have unwanted side effects. Solution APIRX has two granted patents for ophthalmic formulations of cannabinoids. - Anecdotal evidence to support therapeutic benefit for cannabis and cannabinoids in treatment of ophthalmic conditions including: Glaucoma Conjunctivitis Age related macular degeneration Dry eye syndrome Proposed therapeutic effect is derived from the neuroprotective, anti-inflammatory and anti-microbial activities of cannabinoids. exec-jamu273prd Competitive Advantage There are no approved ophthalmic cannabinoid forumations for any indication. 1) https://www.researchandmarkets.com/reports/5441857/glaucoma-therapeutics-market-global-industry?utm_source=BW&utm_medium-PressRelease&utm_code=b2jfrg&utm__ campaign=1608079+-+Global+Glaucoma+Therapeutics+Market+(2021+to+2026)+-+Industry+Trends%2c+Share%2c+Size%2c+Growth%2c+Opportunity+and+Forecasts&utm_ Next Step: Phase 1 - Safety and proof of concept clinical trials. Incannex 2) https://www.fortunebusinessinsights.com/conjunctivitis-treatment-market-103488#:-:text-The%20global%20 3) https://www.verifiedmarketresearch.com/product/macular-degeneration-treatment-market/ conjunctivitis%20treatment%20market, inner%20surface%20of%20the%20eyelid 4) https://www.fortunebusinessinsights.com/dry-eye-syndrome-market-102413 Addressable Market (a) Lead Assets Glaucoma US$ 6.8B¹in2 in 2020 Conjunctivitis US$ 3.9B² AMD US$ 7.5B³ in 2020 Dry eye US$ 5.2B4 in 2012 in 2019 Total US$ 23.4B a) Frost & Sullivan Market Report as commissioned by APIRX, Oct. 2021 Shareholder Presentation 22

View entire presentation